Author: admin

Muscle Invasive Bladder Cancer Pipeline 2025: Clinical Trials, Revenue Share, Medication, Treatment Drugs, Companies by DelveInsight

“Muscle Invasive Bladder Cancer Pipeline”
Muscle Invasive Bladder Cancer companies are Merck Sharp & Dohme LLC, Aura Biosciences, Janssen Research & Development, LLC, Asieris Pharmaceuticals, RemeGen Co., Ltd. and others.

Muscle Invasive Bladder Cancer Pipeline Summary

The Muscle Invasive Bladder Cancer (MIBC) Pipeline has the active involvement of 10+ global companies, including Merck, Janssen, Aura Biosciences, AstraZeneca, Roche, and RemeGen, developing innovative therapies for MIBC. Key investigational drugs such as AU-011, TAR-200, KEYNOTE-905/EV-303, RC48-ADC + JS001, and Imfinzi (durvalumab) are advancing across Phase I–III clinical trials, with several landmark results reported in 2024-2025. Notably, Merck and AstraZeneca announced positive outcomes from Phase III studies evaluating immunotherapy combinations with cystectomy, while Roche and Janssen reported advances in adjuvant and intravesical therapies.

 

The Muscle Invasive Bladder Cancer Pipeline Insight, 2025 report by DelveInsight provides an extensive evaluation of the therapeutic landscape, highlighting 10+ key companies advancing over 10 investigational therapies. The analysis encompasses clinical trial progress, mechanisms of action, routes of administration, and ongoing development activities. The report offers a comprehensive commercial and clinical assessment of candidates from preclinical to marketed stages, with detailed insights into drug mechanisms, study outcomes, regulatory milestones, and product development strategies. It further covers technology platforms, collaborations, mergers and acquisitions, funding initiatives, designations, and other relevant updates shaping the Muscle Invasive Bladder Cancer pipeline.

 

Discover the latest clinical progress, investigational therapies, and strategic developments shaping the Muscle Invasive Bladder Cancer Pipeline. Get detailed analysis of leading drugs, companies, and market opportunities @ Muscle Invasive Bladder Cancer Pipeline Analysis

 

Some of the key takeaways from the Muscle Invasive Bladder Cancer Pipeline Report:

  • Muscle Invasive Bladder Cancer Companies across the globe are diligently working toward developing 10+ Muscle Invasive Bladder Cancer treatment therapies with a considerable amount of success over the years.
  • Muscle Invasive Bladder Cancer companies working in the treatment market are Merck Sharp & Dohme LLC, Aura Biosciences, Janssen Research & Development, LLC, Asieris Pharmaceuticals, RemeGen Co., Ltd. and others, are developing therapies for the Muscle Invasive Bladder Cancer treatment
  • Emerging Muscle Invasive Bladder Cancer therapies such as AU-011, TAR-200, KEYNOTE-905/EV-303, RC48-ADC Combined with JS001, and others are expected to have a significant impact on the Muscle Invasive Bladder Cancer market in the coming years.
  • In July 2025, Merck has announced results of its Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)
  • In June 2025, Hoffmann-La Roche has announced results of a Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
  • In May 2025, AstraZeneca’s Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery to remove the bladder).
  • In March 2025, AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapyafter radical cystectomy (surgery to remove the bladder) has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).
  • In June 2024, Janssen Research & Development announced results of a Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
  • In May 2024, Merck Sharp & Dohme LLC announced results of a Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)
  • In February 2024, RemeGen Co., Ltd announced results of an Open-label, Single-arm, Multi-center, Phase II Study to Evaluate the Efficacy and Safety of RC48-ADC Combined With JS001 in Perioperative Treatment of Muscle-Invasive Bladder Cancer

 

Muscle Invasive Bladder Cancer Overview

Muscle Invasive Bladder Cancer (MIBC) is a serious and aggressive type of bladder cancer in which cancer cells grow into the muscle wall of the bladder. Unlike non–muscle invasive bladder cancer, which is limited to the inner lining, MIBC carries a much higher risk of spreading to other parts of the body and is often linked with poor survival outcomes.

The disease most commonly affects older adults, with smoking, chemical exposure, and chronic bladder irritation being the leading risk factors. Common symptoms include blood in urine (hematuria), pelvic pain, and frequent urination. Diagnosis is confirmed through cystoscopy, biopsy, and imaging scans to determine the stage and spread of the cancer.

Treatment for MIBC typically involves radical cystectomy (removal of the bladder) with lymph node dissection, often combined with neoadjuvant chemotherapy to improve survival. For patients unable to undergo surgery, options include bladder-preserving trimodal therapy (TMT), immunotherapy, or targeted therapy. Recently, immune checkpoint inhibitors (PD-1/PD-L1 inhibitors) have shown promising results in advanced or recurrent cases.

Despite advancements, MIBC remains a challenging condition with high recurrence and mortality rates, highlighting the urgent need for new therapies and personalized treatment approaches.

 

Get a Free Sample PDF Report to know more about Muscle Invasive Bladder Cancer Pipeline Therapeutic Assessment- Muscle Invasive Bladder Cancer Treatment Market

 

Muscle Invasive Bladder Cancer Route of Administration

Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Muscle Invasive Bladder Cancer Molecule Type

Muscle Invasive Bladder Cancer Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Muscle Invasive Bladder Cancer Pipeline Therapeutics Assessment

  • Muscle Invasive Bladder Cancer Assessment by Product Type
  • Muscle Invasive Bladder Cancer By Stage and Product Type
  • Muscle Invasive Bladder Cancer Assessment by Route of Administration
  • Muscle Invasive Bladder Cancer By Stage and Route of Administration
  • Muscle Invasive Bladder Cancer Assessment by Molecule Type
  • Muscle Invasive Bladder Cancer by Stage and Molecule Type

 

DelveInsight’s Muscle Invasive Bladder Cancer Pipeline Report covers around 10+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Gain in-depth insights into pipeline drugs by route of administration, molecule type, and clinical stage. Stay ahead with detailed therapeutic assessments and development updates – Muscle Invasive Bladder Cancer Therapeutics Market

 

Muscle Invasive Bladder Cancer Pipeline Analysis:

TAR-200: Janssen Research & Development, LLC

TAR-200 is an innovative investigational drug delivery system designed to provide controlled and sustained release of gemcitabine directly into the bladder, ensuring prolonged local drug exposure for several weeks. Its safety and efficacy are currently being assessed in Phase II and Phase III clinical trials, including the SunRISe-2 and SunRISe-4 studies, targeting patients with Muscle Invasive Bladder Cancer (MIBC). At present, TAR-200 is in the Phase III stage of development for the treatment of MIBC.

AU-011: Aura Biosciences

AU-011 is a novel, first-in-class targeted therapeutic agent under development for both Muscle Invasive Bladder Cancer and Non-Muscle Invasive Bladder Cancer. Developed by Aura Biosciences, AU-011 functions as a death stimulant and photosensitizer, while also inducing reactive oxygen species (ROS), thereby promoting cancer cell destruction. The therapy is currently undergoing evaluation in Phase I clinical trials for the treatment of MIBC.

 

Discover the latest advancements in Muscle Invasive Bladder Cancer treatments. Explore insights on TAR-200, AU-011, and other emerging therapies in clinical trials. Request a sample report today @ Muscle Invasive Bladder Cancer Clinical Trials and FDA Approvals

 

Scope of Muscle Invasive Bladder Cancer Pipeline Drug Insight

  • Coverage: Global
  • Key Muscle Invasive Bladder Cancer Companies: Afimmune, MediciNova, Mariposa Health Limited, MedWell Laboratories, BioElectron Technology, CSPC Ouyi Pharmaceutical, Veralox Therapeutics, Qurient Therapeutics, PTC Therapeutics and others.
  • Key Muscle Invasive Bladder Cancer Therapies: Epeleuton, Tipelukast, TA 270, MW 001, PTC 857, Baicalein, VLX 1005, Research programme: 5-Muscle Invasive Bladder Cancer Inhibitor (LOX Inhibitor), and others.
  • Muscle Invasive Bladder Cancer Therapeutic Assessment: Muscle Invasive Bladder Cancer current marketed and Muscle Invasive Bladder Cancer emerging therapies
  • Muscle Invasive Bladder Cancer Market Dynamics: Muscle Invasive Bladder Cancer market drivers and Muscle Invasive Bladder Cancer market barriers

 

Request for Sample PDF Report for Muscle Invasive Bladder Cancer Pipeline Assessment and clinical trials – Muscle Invasive Bladder Cancer Drugs and Therapies

 

Table of Contents

  1. Muscle Invasive Bladder Cancer Report Introduction
  2. Muscle Invasive Bladder Cancer Executive Summary
  3. Muscle Invasive Bladder Cancer Overview
  4. Muscle Invasive Bladder Cancer- Analytical Perspective In-depth Commercial Assessment
  5. Muscle Invasive Bladder Cancer Pipeline Therapeutics
  6. Muscle Invasive Bladder Cancer Late Stage Products (Phase II/III)
  7. Muscle Invasive Bladder Cancer Mid Stage Products (Phase II)
  8. Muscle Invasive Bladder Cancer Early Stage Products (Phase I)
  9. Muscle Invasive Bladder Cancer Preclinical Stage Products
  10. Muscle Invasive Bladder Cancer Therapeutics Assessment
  11. Muscle Invasive Bladder Cancer Inactive Products
  12. Company-University Collaborations (Licensing/Partnering) Analysis
  13. Muscle Invasive Bladder Cancer Companies
  14. Muscle Invasive Bladder Cancer Key Products
  15. Muscle Invasive Bladder Cancer Unmet Needs
  16. Muscle Invasive Bladder Cancer Market Drivers and Barriers
  17. Muscle Invasive Bladder Cancer Future Perspectives and Conclusion
  18. Muscle Invasive Bladder Cancer Analyst Views
  19. Appendix
  20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Muscle Invasive Bladder Cancer Pipeline 2025: Clinical Trials, Revenue Share, Medication, Treatment Drugs, Companies by DelveInsight

Prostate Cancer Pipeline Outlook 2025 – Clinical Trials, Treatment, ROA, Medication, MOA, Revenue Share, Companies by DelveInsight

“Prostate Cancer Pipeline”
The prostate cancer pipeline is experiencing unprecedented growth, driven by 150+ active players, breakthrough therapies, and recent FDA fast-track designations, signaling a transformative decade ahead in prostate cancer treatment.

Prostate Cancer Pipeline Summary

The Prostate Cancer pipeline is rapidly evolving, with over 150 companies exploring novel therapies across all clinical stages. Recent developments include FDA fast-track designations, new companion diagnostic approvals, and promising trial outcomes for drugs like NUBEQA®, Xtandi™, and Cabometyx®. Emerging therapies such as Janssen’s Niraparib (Phase III), Zenith’s ZEN-3694 (Phase II), Seagen’s Ladiratuzumab vedotin (Phase II), Fortis’ FOR46 (Phase I/II), and Regeneron’s REGN5678 (Phase I/II) highlight diverse mechanisms, from PARP inhibition to antibody-drug conjugates and bispecifics. Collectively, these advances reflect growing innovation and investment in prostate cancer treatment, aiming to improve survival and outcomes.

DelveInsight’s “Prostate Cancer Pipeline Insight 2025” report offers an in-depth analysis of the global prostate cancer pipeline, covering therapies in various stages of clinical development and highlighting the efforts of leading pharmaceutical companies to advance this space. According to DelveInsight’s assessment, the prostate cancer pipeline comprises more than 150 key companies actively engaged in developing over 160 therapeutic candidates. The report provides detailed insights into clinical trials, mechanisms of action, routes of administration, and recent developmental activities, while also evaluating the future growth potential of the prostate cancer treatment landscape.

 

Get your free sample of the Prostate Cancer Pipeline Report today and gain strategic insights to identify opportunities, assess competitors, and strengthen your pipeline decisions @ Prostate Cancer Pipeline Report

 

Key Takeaways from the Prostate Cancer Pipeline Report

  • DelveInsight’s prostate cancer pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline prostate cancer drugs.
  • Key prostate cancer companies such as Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, LAVA Therapeutics, Essa Pharma, Poseida Therapeutics, Janux Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, AbbVie, SL VAXiGEN, Sorrento Therapeutics, Inc., 858 Therapeutics, Avacta Life Sciences Ltd, Nammi Therapeutics, BeiGene, DualityBio, and others are evaluating new prostate cancer drugs to improve the treatment landscape.
  • Promising pipeline prostate cancer such as 177Lu-PSMA-I&T, Opevesostat (MK-5684), 177Lu-DOTA-rosopatamab, Cabozantinib, Capivasertib, Masitinib, FPI-2265, 177Lu-PNT2002, Mevrometostat (PF-06821497), Fuzuloparib, ModraDoc006, BMS-986218, Lorigerlimab, SX-682, ZEN-3694, Vudalimab, OPDIVO (nivolumab), Zenocutuzumab, Vobramitamab Duocarmazine, PT-112, LAE201, TAVT-45, pTVG-HP (MVI-816), TAS-115, KPG-121, ARV-766, CAN-2409, Saruparib (AZD5305), 177Lu-rhPSMA-10.1, Tazemetostat (Tazverik), KEYTRUDA, LAVA-1207, Masofaniten (EPI-7386), P PSMA 101, JANX 007, AUR107, MSP008-22, 225Ac-FL-020, NPX267, ABBV-969, SL-T10, Abivertinib, ETX-19477, AVA 6000, QXL138AM, BG-68501, DB-1311, and others are under different phases of prostate cancer clinical trials.
  • In August 2025, Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of therapies called RIPTAC™ Therapeutics, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to HLD-0915, the company’s lead development candidate, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
  • In July 2025, Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its novel drug, TRE-515, in the treatment of prostate cancer. TRE-515 is currently in phase 1 clinical trials for solid tumors. The FTD to TRE-515 in combination with radioligand therapy for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration resistant prostate cancer (mCRPC), a condition impacting thousands of patients. PSMA, an important disease biomarker, is detected in over 80% of prostate cancer cases, enabling earlier identification and intervention.
  • In July 2025, AB Science SA (Euronext – FR0010557264 – AB) announced that a confirmatory phase 3 trial of masitinib in metastatic castrate resistant prostate cancer (study AB22007) has been authorized by FDA and EMA (harmonized protocol approved through step 1 of Clinical Trials Information System), with a biomarker that targets patients with less advanced metastatic disease.
  • In June 2025, Orion’s collaboration partner Bayer announced that the U.S. Food and Drug Administration (FDA) has approved the oral androgen receptor inhibitor (ARi) darolutamide in combination with androgen deprivation therapy (ADT) for use in patients with metastatic castration-sensitive prostate cancer (mCSPC), which is also known as metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on positive results from the pivotal Phase III ARANOTE trial, which showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001) in patients with mHSPC.
  • In May 2025, Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CAN-2409 (aglatimagene besadenovec), the Company’s biological immunotherapy lead candidate, for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease. CAN-2409 was also previously granted FDA Fast Track designation for the same indication.
  • March 2025: The FDA approved Telix Pharmaceuticals’ NDA for TLX007-CDx (Gozellix), a diagnostic imaging agent for prostate cancer.
  • March 2025: Quibim received FDA 510(k) clearance for its QP-Prostate® CAD solution, designed to enhance prostate cancer lesion detection, supporting more accurate diagnosis and treatment planning.
  • February 2025: Ibex Medical Analytics secured FDA 510(k) clearance for Ibex Prostate Detect, an AI-driven diagnostic tool that generates heatmaps to help pathologists identify small or rare prostate cancers that may otherwise be overlooked.
  • January 2025: The FDA granted Fast Track Designation (FTD) to Clarity Pharmaceuticals’ 64Cu-SAR-bisPSMA, a PET imaging agent for detecting PSMA-positive prostate cancer lesions in patients experiencing biochemical recurrence (BCR) after definitive therapy.
  • January 2025: Clarity Pharmaceuticals also announced another FTD approval for 64Cu-SAR-bisPSMA, enabling expedited clinical development and regulatory review, potentially speeding up its availability for prostate cancer patients.
  • In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx and atezolizumab in mCRPC showed a non-significant improvement in overall survival but met the progression-free survival (PFS) endpoint.
  • In August 2024, Nuvation Bio announced that the US Food and Drug Administration cleared its investigational new drug application to evaluate NUV-1511, the first clinical candidate from the company’s novel drug-drug conjugate (DDC) platform.
  • In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for metastatic castrate-resistant prostate cancer (mCRPC).
  • In June 2024, Kangpu Biopharmaceuticals received FDA approval for a Phase II/III trial of KPG-121 with Abiraterone for mCRPC.
  • In June 2024, BioNTech SE and Duality Biologics announced that the US Food and Drug Administration granted Fast Track designation for BNT324/DB-1311 for the treatment of patients with advanced/unresectable, or metastatic castration-resistant prostate cancer (“CRPC”) who have progressed on or after standard systemic regimens.

 

With 150+ players and 160+ pipeline drugs, the prostate cancer space is evolving rapidly. Get your copy of DelveInsight’s Prostate Cancer Pipeline Report to stay competitive @ Prostate Cancer Pipeline Analysis

 

Prostate Cancer Overview

Prostate cancer is one of the most common cancers affecting men, particularly those over the age of 50. It develops in the prostate gland, a small walnut-shaped organ responsible for producing seminal fluid. While many prostate cancers grow slowly and may remain asymptomatic for years, aggressive forms can spread rapidly to bones and other organs, making early detection essential.

The primary risk factors of Prostate cancer include advanced age, family history, genetic mutations, and certain lifestyle factors. African American men and those with a family history of prostate or breast cancer are at higher risk. Common symptoms may include difficulty urinating, weak urine flow, pelvic discomfort, or blood in urine. However, in early stages, prostate cancer may not cause noticeable signs.

Prostate cancer Diagnosis typically involves prostate-specific antigen (PSA) blood tests, digital rectal exams (DRE), imaging techniques like MRI, and biopsy confirmation. Prostate cancer Treatment strategies depend on the stage, aggressiveness, and overall health of the patient. Options include active surveillance, surgery, radiation therapy, hormone therapy, chemotherapy, and newer targeted or immunotherapy approaches.

Rising awareness, advanced diagnostic tools, and novel therapies are improving survival rates and patient outcomes are some of the factors affecting Prostate cancer market. Timely screening and personalized treatment remain crucial in managing prostate cancer effectively.

 

A snapshot of the Pipeline Prostate Cancer Drugs mentioned in the report:

  • 177Lu-PSMA-I&T: Curium
  • Opevesostat (MK-5684; ODM-208): Merck/ Orion
  • Mevrometostat (PF-06821497): Pfizer
  • TRUQAP (capivasertib, AZD5363): AstraZeneca
  • 177Lu-PNT2002: Lantheus
  • 177Lu-DOTA-rosopatamab (TLX591): Telix Pharmaceuticals
  • TAVT-45 (abiraterone acetate): Tavanta Therapeutics
  • Saruparib (AZD5305): AstraZeneca
  • CAN-2409 (aglatimagene besadenovec): Candel Therapeutics
  • Fuzuloparib: Jiangsu Hengrui Pharmaceuticals

 

Discover key players, breakthrough therapies, regulatory updates, and late-stage clinical trials shaping the future of prostate cancer treatment. @ Prostate Cancer Clinical Trials and FDA Approvals

 

Prostate Cancer Therapeutics Assessment

Niraparib (Janssen Research & Development/GSK)

Niraparib is an oral PARP inhibitor marketed as ZEJULA by GSK’s oncology division. Janssen holds rights for prostate cancer development (excluding Japan) through a partnership with TESARO. Already approved in ovarian cancers, niraparib is in Phase III trials for mCRPC and mCSPC.

 

ZEN-3694 (Zenith Epigenetics)

ZEN-3694 is an oral BET inhibitor that blocks bromodomain proteins (BRD2, BRD3, BRD4, BRDT) involved in tumor growth and survival. By targeting oncogenic super enhancers, it may disrupt cancer proliferation, metastasis, and immune evasion. It is currently in Phase II development for prostate cancer.

 

Ladiratuzumab Vedotin (Seagen)

This ADC targets LIV-1, expressed in several cancers including prostate cancer. Using Seagen’s ADC technology, it links a LIV-1–directed antibody to the cytotoxic agent MMAE. It works by delivering targeted cell death and may also trigger immune responses. The therapy is under Phase II evaluation for prostate cancer.

 

FOR46 (Fortis Therapeutics)

FOR46 is an antibody-drug conjugate directed against CD46, a target highly expressed in prostate cancer and multiple myeloma. The drug is in Phase I/II trials for metastatic castration-resistant prostate cancer (mCRPC).

 

REGN5678 (Regeneron Pharmaceuticals)

REGN5678 is a bispecific antibody that binds CD28 on T cells and PSMA on tumor cells, helping T cells attack prostate cancer with reduced toxicity risk compared to CD3 bispecifics. It is in Phase I/II development.

 

Prostate Cancer Phases

DelveInsight’s report highlights over 150 products across multiple stages of clinical development, including:

  • Late-stage therapies (Phase III)
  • Mid-stage therapies (Phase II)
  • Early-stage therapies (Phase I), along with details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive therapies

 

Stay ahead with therapeutic assessments across multiple molecule types and MoAs. For further information on the prostate cancer pipeline therapeutics, reach out @ Prostate Cancer Therapeutics Market

 

Prostate Cancer Drugs Route of Administration

The Prostate Cancer pipeline report evaluates drugs based on their Route of Administration (ROA). Candidates are classified into categories such as:

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Prostate Cancer Drugs Molecule Type

Pipeline products are also segmented by Molecule Type, including:

  • Monoclonal Antibodies
  • Peptides
  • Polymers
  • Small Molecules
  • Gene Therapies

 

Scope of the Prostate Cancer Pipeline Report

  • Coverage: Global
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
  • Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
  • Therapeutics Assessment By Mechanism of Action: PSMA inhibitors (Prostate-specific Membrane Antigen Inhibitors), CYP11A1 inhibitor, EZH2 inhibitor, Proto-oncogene protein c-akt inhibitor, PSMA-targeted therapy, Ionising radiation emitter, Steroidal inhibitor of CYP17A1, Poly(ADP-ribose) polymerase-1 inhibitor, Thymidine kinase expression stimulants, Poly(ADP-ribose) polymerase 2 inhibitors
  • Key Prostate Cancer Companies: Merck & Co., Inc. (NYSE: MRK), Telix Pharmaceuticals Limited (ASX: TLX), Exelixis, Inc. (NASDAQ: EXEL), AstraZeneca PLC (NASDAQ: AZN), AB Science S.A. (EPA: AB), Lantheus Holdings, Inc. (NASDAQ: LNTH), Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb Company (NYSE: BMY), MacroGenics, Inc. (NASDAQ: MGNX), Xencor, Inc. (NASDAQ: XNCR), Merus N.V. (NASDAQ: MRUS), Arvinas, Inc. (NASDAQ: ARVN), Candel Therapeutics, Inc. (NASDAQ: CADL), Ipsen S.A. (EPA: IPN), LAVA Therapeutics N.V. (NASDAQ: LVTX), ESSA Pharma Inc. (NASDAQ: EPIX), Poseida Therapeutics, Inc. (NASDAQ: PSTX), Janux Therapeutics, Inc. (NASDAQ: JANX), AbbVie Inc. (NYSE: ABBV), Sorrento Therapeutics, Inc. (OTC: SRNEQ), Avacta Group plc (LSE: AVCT), BeiGene, Ltd. (NASDAQ: BGNE), Duality Biologics (HKEX: 6988), Curium, Modra Pharmaceuticals, Syntrix Pharmaceuticals, Zenith Epigenetics, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Blue Earth Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, SL VAXiGEN, Nammi Therapeutics, and 858 Therapeutics, and others
  • Key Prostate Cancer Pipeline Therapies: 177Lu-PSMA-I&T, Opevesostat (MK-5684), 177Lu-DOTA-rosopatamab, Cabozantinib, Capivasertib, Masitinib, FPI-2265, 177Lu-PNT2002, Mevrometostat (PF-06821497), Fuzuloparib, ModraDoc006, BMS-986218, Lorigerlimab, SX-682, ZEN-3694, Vudalimab, OPDIVO (nivolumab), Zenocutuzumab, Vobramitamab Duocarmazine, PT-112, LAE201, TAVT-45, pTVG-HP (MVI-816), TAS-115, KPG-121, ARV-766, CAN-2409, Saruparib (AZD5305), 177Lu-rhPSMA-10.1, Tazemetostat (Tazverik), KEYTRUDA, LAVA-1207, Masofaniten (EPI-7386), P PSMA 101, JANX 007, AUR107, MSP008-22, 225Ac-FL-020, NPX267, ABBV-969, SL-T10, Abivertinib, ETX-19477, AVA 6000, QXL138AM, BG-68501, DB-1311, and others

 

Explore the latest prostate cancer pipeline therapies — from PARP inhibitors to next-gen ADCs and bispecifics. Get competitive insights on Janssen, GSK, Seagen, Fortis & Regeneron. @ Prostate Cancer Drugs and Therapies

 

Table of Contents

1. Prostate Cancer Pipeline Report Introduction

2. Prostate Cancer Pipeline Report Executive Summary

3. Prostate Cancer Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Prostate Cancer Clinical Trial Therapeutics

6. Prostate Cancer Pipeline: Late-Stage Products (Pre-registration)

7. Prostate Cancer Pipeline: Late-Stage Products (Phase III)

8. Prostate Cancer Pipeline: Mid-Stage Products (Phase II)

9. Prostate Cancer Pipeline: Early-Stage Products (Phase I)

10. Prostate Cancer Pipeline Therapeutics Assessment

11. Inactive Products in the Prostate Cancer Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key Prostate Cancer Companies

14. Key Products in the Prostate Cancer Pipeline15. Prostate Cancer Unmet Needs

16. Prostate Cancer Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prostate Cancer Pipeline Outlook 2025 – Clinical Trials, Treatment, ROA, Medication, MOA, Revenue Share, Companies by DelveInsight

Hyperphosphatemia Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

“Hyperphosphatemia Market”
Hyperphosphatemia market in the 7MM was valued at approximately USD 4 billion in 2023 and is projected to grow, driven by rising chronic kidney disease (CKD) prevalence and an expanding patient pool.

Hyperphosphatemia Market Summary

Hyperphosphatemia, defined as elevated serum phosphate levels (>4.5 mg/100 mL), commonly affects CKD patients due to impaired renal function. The United States accounted for nearly 50% of total cases in 2023 and represents the largest market, followed by the EU4, the United Kingdom, and Japan. Hyperphosphatemia market growth is expected from improved uptake of existing drugs, increased awareness, and the anticipated launch of advanced therapies, including one-time gene treatments. In 2023, the U.S. had about 600,000 end-stage renal disease (ESRD) patients on dialysis, a number expected to rise. Approved phosphate binders include KIKLIN, AURYXIA/RIONA, and VELPHORO/P-TOL. Recently, XPHOZAH gained FDA approval for dialysis patients intolerant to binders, while Oxylanthanum Carbonate (OLC) is emerging as a promising therapy.

 

DelveInsight’s “Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast–2034” report provides a comprehensive evaluation of Hyperphosphatemia, encompassing historical trends and projected epidemiology, along with market dynamics across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The analysis details current therapeutic practices, emerging treatment options, market share distribution among available therapies, and the estimated market size for Hyperphosphatemia from 2020 to 2034 across seven major markets. Additionally, the report examines prevailing treatment algorithms, key market drivers and barriers, and existing unmet clinical needs, thereby identifying strategic opportunities and assessing the growth potential of the Hyperphosphatemia market.

 

The $4B Hyperphosphatemia market is evolving fast with new therapies like XPHOZAH & OLC. Get DelveInsight’s latest Hyperphosphatemia Market Forecast (2020–2034) for growth trends, pipeline insights & strategic opportunities @ Hyperphosphatemia Market Outlook

 

Some facts of the Hyperphosphatemia Market Report are:

  • According to DelveInsight, The hyperphosphatemia market in the 7MM was valued at approximately USD 4 billion in 2023.
  • Leading Hyperphosphatemia companies working in the market are Phosphate Therapeutics, Bayer, Shire, Kyowa Kirin Co Ltd, Shanghai Alebund Pharmaceuticals Limited, Ardelyx, Kissei Pharmaceutical Co. Ltd., Taisho Pharmaceutical Co. Ltd., Sanofi, Chugai Pharmaceutical, Astellas Pharma Inc., Alebund Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, KDL Inc., Denver Nephrologists, CM&D Pharma Limited, Daiichi Sankyo and others.
  • Key Hyperphosphatemia Therapies are Oxylanthanum Carbonate (OLC), KIKLIN, VELPHORO/P-TAL, AURYXIA/ RIONA, and many others.
  • In June 2025, Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced that the U.S. Food and Drug Administration (FDA) has issued a CRL for its New Drug Application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
  • In June 2025, Alebund Pharmaceuticals (“Alebund” or the “Company”), an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and related chronic conditions, announced the database lock was achieved on June 16, 2025 for the pivotal phase 3 study of its investigational drug AP301, a new generation of oral iron-based phosphate binder, in dialysis patients with hyperphosphatemia. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in serum phosphorus control with AP301. The safety profile of AP301 is favorable and consistent with previous studies.
  • In February 2025, Ardelyx Gains Approval for Tenapanor to Treat hyperphosphatemia. Ardelyx has announced that China’s National Medical Products Administration (NMPA) has approved tenapanor for controlling serum phosphorus levels in dialysis patients with chronic kidney disease (CKD).

 

Hyperphosphatemia Overview

Hyperphosphatemia is a metabolic disorder characterized by abnormally elevated serum phosphate levels, typically defined as concentrations exceeding 4.5 mg/dL. It is most commonly observed in patients with chronic kidney disease (CKD), particularly those in advanced stages or undergoing dialysis, due to the kidneys’ reduced ability to excrete phosphate efficiently. The condition is clinically significant because persistently high phosphate levels can lead to vascular calcification, cardiovascular complications, secondary hyperparathyroidism, and bone-mineral disorders, collectively increasing morbidity and mortality in CKD patients.

The prevalence of hyperphosphatemia closely parallels the rising global burden of CKD and end-stage renal disease (ESRD). In 2023, the United States accounted for nearly half of the total hyperphosphatemia cases across the seven major markets (7MM), highlighting its substantial clinical and economic impact. Current management strategies primarily involve dietary phosphate restriction, dialysis optimization, and the use of phosphate binders, which are classified into calcium-based and non-calcium-based agents. Despite their effectiveness, treatment adherence remains a challenge due to pill burden and gastrointestinal side effects.

Ongoing research focuses on novel therapies such as iron-based binders, new molecular agents, and gene therapy approaches to address unmet needs. Rising awareness, better diagnostics, and emerging treatment options are expected to reshape the market outlook.

 

Access in-depth insights on Hyperphosphatemia key players, therapies, market drivers, barriers, and opportunities across the 7MM @ Hyperphosphatemia Clinical Trials and FDA Approvals

 

Hyperphosphatemia Market Outlook

In the hyperphosphatemia landscape, companies such as Unicycive Therapeutics are advancing lead candidates through various stages of clinical development to expand treatment options. The 7MM market is largely driven by the use of phosphate binders (both calcium-based and calcium-free) along with off-label therapies. In 2023, the United States accounted for the largest share, with a market size of approximately USD 2,400 million. Within the EU4 and the UK, Germany contributed the most, with around USD 150 million.

 

Hyperphosphatemia Market Drivers

  • Rising CKD and ESRD prevalence: Growing patient pool, particularly those on dialysis, increases hyperphosphatemia incidence.
  • Improved diagnostic rates: Enhanced awareness and early detection of CKD-associated complications drive treatment demand.
  • Pipeline innovations: Emerging therapies (e.g., Oxylanthanum Carbonate, novel gene therapies) expected to expand treatment landscape.
  • Regulatory approvals: New drug approvals (e.g., XPHOZAH, 2023 FDA approval) strengthen treatment options.
  • Shift toward non-calcium-based binders: Preference for safer, effective alternatives fuels adoption.
  • Rising awareness among physicians and patients: Better disease education promotes compliance and treatment uptake.

 

Hyperphosphatemia Market Barriers

  • Treatment compliance issues: Phosphate binders often require multiple daily doses, impacting adherence.
  • Adverse effects of therapies: Gastrointestinal intolerance and other side effects limit long-term use.
  • Cost constraints: High pricing of newer therapies poses affordability challenges, especially in emerging markets.
  • Limited novel mechanisms of action: Market still dominated by phosphate binders with incremental innovations.
  • Slow penetration of advanced therapies: Gene therapies and novel drugs face long regulatory and clinical timelines.
  • Unmet needs in refractory patients: Some patients remain unresponsive or intolerant to existing binders.

 

Interested to know how the emerging diagnostic approaches will be contributing in increased Hyperphosphatemia diagnosed prevalence pool? Download report @ Hyperphosphatemia Patient Pool

 

Hyperphosphatemia Epidemiology

The Hyperphosphatemia epidemiology section provides insights into the historical and current Hyperphosphatemia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. In 2023, the United States recorded the highest prevalence of hyperphosphatemia in the 7MM, with ~500,000 cases, alongside ~2.4 million CKD stage 3–5 patients. Japan ranked second, contributing ~300,000 cases, while Germany led among the EU4 and the UK with ~56,000 cases.

Hyperphosphatemia Epidemiology Segmentation:

  • Total Prevalent Cases of Chronic Kidney Disease (CKD)
  • Total Diagnosed Prevalent Cases of CKD
  • Stage-specific Distribution of CKD
  • Total Prevalent Cases of End-Stage Renal Disease (ESRD)
  • Number of ESRD Patients Undergoing Dialysis
  • Total Prevalent Cases of Hyperphosphatemia

 

Hyperphosphatemia Drugs Uptake

VELPHORO/P-TOL (Fresenius Medical Care/Vifor Pharma)

Approved in the US (2013) and Europe (2014), VELPHORO (sucroferric oxyhydroxide) is widely marketed, including Japan (as P-TOL since 2018 through Kissei). It is available in over 30 countries, benefitting more than 100,000 patients annually.

KIKLIN (Astellas Pharma)

An amine-functional polymer (bixalomer) approved in 2012 for CKD patients on dialysis, with its indication expanded in 2016 to include all CKD-related hyperphosphatemia. It lowers phosphate absorption by binding in the GI tract.

Oxylanthanum Carbonate (OLC, Unicycive Therapeutics)

A novel nanoparticle-based phosphate binder designed to reduce pill burden by enabling smaller, easier-to-swallow tablets. Phase II trials have shown strong safety and tolerability, with FDA submission planned via the 505(b)(2) pathway.

 

Discover how VELPHORO, KIKLIN, and OLC are shaping the Hyperphosphatemia market. Get insights on drug uptake trends, pipeline shifts, and growth opportunities.

Download your sample report now! @ Hyperphosphatemia Medication and Companies

 

Hyperphosphatemia Therapeutics Assessment

Major key companies are working proactively in the Hyperphosphatemia Therapeutics market to develop novel therapies which will drive the Hyperphosphatemia treatment markets in the upcoming years are Phosphate Therapeutics, Bayer, Shire, Kyowa Kirin Co Ltd, Shanghai Alebund Pharmaceuticals Limited, Ardelyx, Kissei Pharmaceutical Co. Ltd., Taisho Pharmaceutical Co. Ltd., Sanofi, Chugai Pharmaceutical, Astellas Pharma Inc., Alebund Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, KDL Inc., Denver Nephrologists, CM&D Pharma Limited, Daiichi Sankyo and others.

 

Discover how leading pharma innovators are reshaping the Hyperphosphatemia treatment algorithm with novel therapies? Download sample report @ Hyperphosphatemia Clinical Trials and FDA Approvals

 

Hyperphosphatemia Report Key Insights

1. Hyperphosphatemia Patient Population

2. Hyperphosphatemia Market Size and Trends

3. Key Cross Competition in the Hyperphosphatemia Market

4. Hyperphosphatemia Market Dynamics (Key Drivers and Barriers)

5. Hyperphosphatemia Market Opportunities

6. Hyperphosphatemia Therapeutic Approaches

7. Hyperphosphatemia Pipeline Analysis

8. Hyperphosphatemia Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Hyperphosphatemia Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Hyperphosphatemia Competitive Intelligence Analysis

4. Hyperphosphatemia Market Overview at a Glance

5. Hyperphosphatemia Disease Background and Overview

6. Hyperphosphatemia Patient Journey

7. Hyperphosphatemia Epidemiology and Patient Population

8. Hyperphosphatemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Hyperphosphatemia Unmet Needs

10. Key Endpoints of Hyperphosphatemia Treatment

11. Hyperphosphatemia Marketed Products

12. Hyperphosphatemia Emerging Therapies

13. Hyperphosphatemia Seven Major Market Analysis

14. Attribute Analysis

15. Hyperphosphatemia Market Outlook (7 major markets)

16. Hyperphosphatemia Access and Reimbursement Overview

17. KOL Views on the Hyperphosphatemia Market

18. Hyperphosphatemia Market Drivers

19. Hyperphosphatemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hyperphosphatemia Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Brenmiller Energy Stock: Undervalued Clean Tech Play Driven by EU-Backed TES Projects, Nuclear Integration, and Private Market Comps (NASDAQ: BNRG)

Thermal energy storage (TES) is finally getting its breakthrough moment. Brenmiller Energy (NASDAQ: BNRG) is part of it, with its bGen™ platform advancing from proven toward mainstream—a milestone that validates not only its technology but also the TES sector for the efficiencies it delivers.

Rightfully so. Industrial heat accounts for nearly a quarter of global emissions and has long been considered “hard to abate,” since factories require constant, high-temperature energy that only fossil-fuel powered boilers have reliably supplied. Without scalable storage, the industry remained locked into fossil fuels even as renewables gained momentum. However, Brenmiller’s progress marks a turning point—showing, perhaps better said, proving that thermal energy should no longer be considered as an afterthought but rather as the connective tissue that lets industry use clean power when and where it’s needed, 24/7/365.

And the driver is not only engineering but also economics. With contracts secured, financing that lowers risk, and projects in the tens of millions, Brenmiller is putting its TES solutions on the same trajectory that took solar and wind from experiments to infrastructure—only this time the focus is on industrial heat, where the opportunities may be even larger. And the proof isn’t theoretical. It’s already showing up in commercial deployments.

How Brenmiller Is Turning Thermal Storage Into a Commercial Reality

The company’s 32 MWh installation for Tempo Beverages—40% owned by Heineken and the sole Israeli bottler for Pepsi—demonstrates, for instance, how an industrial facility can replace fossil boilers with reliable, renewable-driven heat. Instead of relying on renewable generation to align with production schedules, Tempo will be able to store off-peak electricity and dispatch it as high-quality steam when needed. The result: lower emissions, more predictable costs, and an energy supply that keeps pace with its manufacturing demand.

And behind that outcome is a financing model designed to make adoption easier. Brenmiller’s Heat-as-a-Service (HaaS) model, essentially a long-term agreement where customers pay for clean heat instead of owning the equipment, allows companies to decarbonize, often without upfront capital. Brenmiller guarantees performance, covers operations and maintenance, and takes on risk. It’s the same playbook that made solar power bankable a decade ago, and it positions Brenmillers bGen as a procurement solution, not a science project.

That model—and the bGen™ platform itself—is attracting the right kinds of attention. In April, bGen™ ZERO won the Gold Medal at the 2025 Edison Awards in Energy Storage and Management. Brenmiller has also broadened its footprint. A case-study deployment with the New York Power Authority (NYPA) demonstrated U.S. versatility, and in June, the company signed an MoU in Japan, one of the world’s most demanding industrial markets, to accelerate TES adoption.

Fueling Growth: SMR Integration, EU Backing, and a $25M Funding Catalyst

If adoption proves a technology, platform breadth sustains it. Brenmiller is benefiting from both. The company is developing a nuclear-aligned version of bGen™ designed to integrate with Small Modular Reactors (SMRs), a new generation of compact nuclear plants that can be built faster and operated more flexibly than traditional reactors. Nuclear provides firm baseload power, while TES multiplies its value by storing excess generation and releasing high-temperature heat on demand. That shores up the primary weakness of nuclear power, and more importantly, is the type of flexibility that manufacturers and policymakers need in an increasingly electrified, AI-driven economy.

And Brenmiller isn’t just theorizing about this flexibility—it’s actively building it into its growth strategy. A July MoU targets up to $50 million in SMR-integrated TES projects by 2030, and Brenmiller has also been tapped for support through the EU Innovation Fund, with an estimated €4 million allocation for bGen™. To capitalize on these opportunities, the company secured a funding agreement with Alpha Capital Anstalt, which provides up to $25 million in equity financing, expandable to $50 million if all the warrants are exercised.

This capital gives Brenmiller the runway to accelerate installations under its Heat-as-a-Service model—turning a micro-cap already landing multi-million-dollar projects into one with the financial firepower to scale faster than markets may be pricing in.

Commitments Carry Value Beyond Entire Market Cap

Perhaps the most eye-catching milestone is the Solwyn project in Spain. This £25 million clean-energy initiative aims to replace fossil boilers with renewable energy and storage, with £7 million directly allocated to Brenmiller’s bGen™ systems. For a company trading at only $2.01 per share with a market cap of about $5.5 million at the market close on August 18th, that single project allocation eclipses its entire public valuation and highlights a glaring disconnect between Brenmiller’s market price and the scale of opportunities it is securing.

That disconnect becomes even clearer when compared with private peers. Rondo Energy carried a valuation of roughly $547 million in its Series B round in December 2024, while Antora Energy reported a valuation of about $559 million in February 2024. Because these companies are private, the latest valuations available are not publicly disclosed; however, they still imply multiples of 80 to 85 times BNRG’s current market cap.

Against that backdrop, Brenmiller’s contracts, capitalization, and pipeline suggest that public markets may be materially underestimating the company’s value. And while the long-term story is what matters most, it is worth noting that BNRG stock has already risen by more than 17% since the start of August at its recent $2.01, a sign that the market may be starting to take notice.

Why Brenmiller’s Breakthrough Signals a Mainstream Moment for Thermal Energy Storage

And it should. Thermal energy storage is finally stepping into the role that batteries play for electricity: storing energy when it is cheap or clean and releasing it when it is most valuable. Brenmiller’s recent achievements, including plant-scale deployments, Heat-as-a-Service financing, Gold Medal recognition, nuclear-integration development, EU-backed programs, the Solwyn partnership, and a funding structure to accelerate deployment, all point to one conclusion. TES has crossed the adoption threshold.

For manufacturers, it is now a real procurement option. For governments, it is a practical tool to hit climate targets. And for investors, Brenmiller represents one of the clean-energy sector’s most asymmetric opportunities, a micro-cap stock with technology, validation, capitalization, and contracts that could unlock a future far larger than today’s valuation suggests.

 

Sources and references:

  • https://bren-energy.com/press/

  • https://finance.yahoo.com/quote/BNRG/

  • https://finance.yahoo.com/quote/BNRG/history/

  • https://bren-energy.com/partners-and-distributers/

  • https://bren-energy.com/investors/

  • https://bren-energy.com/wp-content/uploads/2025/07/BNRG_JULY25.pdf

  • https://forgeglobal.com/rondo-energy_ipo/#:~:text=$546.94MM,Log%20In

  • https://forgeglobal.com/antora-energy_ipo/

 

Disclaimers and Disclosures: This content is sponsored. This content was produced by HPM and has not been reviewed or approved by Brenmiller Energy Ltd. The views expressed are solely those of HPM and may not fully align with the company’s official press releases or filings. This content should be considered a third-party perspective only. Hawk Point Media Group, LLC (HPM) has been compensated with ten thousand restricted shares, valued at twenty-five thousand dollars at the time of disbursement from Brenmiller Energy Ltd., as full payment for digital media and consulting services to be provided between August 15, 2025, and December 31, 2025. These shares are payment in full, will not adjust with stock performance, and may not be sold before November 15, 2025. Other than this compensation, HPM does not own, buy, sell, or trade securities of Brenmiller Energy Ltd. HPM also discloses prior service agreements with the company and third parties that expired in April 2025 and 2024, respectively. A complete disclosure of all services and compensation is linked HERE. HPM is not operated by a licensed broker, dealer, or registered investment adviser. Nothing herein constitutes a recommendation to buy or sell any security. HPM reports are commercial advertisements for general information purposes only and do not constitute investment advice. Investing in any publicly traded company involves risk. Investors can and often do lose part or all of their investment. Always perform your own due diligence before making any investment decision.

Forward-Looking Statements: This article contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. The forward-looking statements contained or implied in this article are subject to other risks and uncertainties, many of which are beyond the control of the Company featured or HPM.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Brenmiller Energy Stock: Undervalued Clean Tech Play Driven by EU-Backed TES Projects, Nuclear Integration, and Private Market Comps (NASDAQ: BNRG)

Former Pro Bowler Robert Griffith Joins Armilla Tech as President and Co-Owner

Former Pro Bowler Robert Griffith Joins Armilla Tech as President and Co-Owner
Game-Changing Sports Tech Company Taps Former Viking to Lead the Next Evolution in On-Field Communication

LOS ANGELES, CA – August 19, 2025 – Armilla Tech, a leader in secure on-field communication technology, today announced that NFL Pro Bowler and former Minnesota Vikings star Robert Griffith has joined the company as President and Co-Owner.

Best known for his impact on the field—earning Pro Bowl honors and being named the Vikings’ 2000 NFL Man of the Year—Griffith now brings his strategic mindset and engineering background to the forefront of innovation.

“This technology is about to revolutionize the way coaches and players communicate,” says Griffith. “It’s secure, fast, and built for the future of football—eliminating the communication breakdowns that can cost teams the game.”

Armilla Tech’s patented “On the Field” communication system uses encrypted radio frequencies, bypassing unreliable Wi-Fi, Bluetooth, or cellular signals. It delivers real-time visual and audio play calls through a three-tiered encryption protocol, offering military-grade security and zero interference. This breakthrough benefits not just sports teams, but also law enforcement and tactical units.

Griffith’s leadership and elite-level understanding of the game bring powerful validation to Armilla’s mission. With a degree in Engineering from San Diego State and an MBA from Fordham University, he combines on-field experience with academic and technical expertise.

Call the play. Watch how Armilla Technology wirelessly sends plays from a coach’s tablet to a player’s wrist device.

“Having a visionary like Robert Griffith take the helm with us is more than exciting—it’s a game-changer,” says Lance Heron, CEO and founder of Armilla Tech. “He’s not only passionate about football but also deeply committed to innovation and security.”

Armilla’s technology is already turning heads for its potential to redefine how teams operate, enabling secure, real-time communication with unmatched clarity and protection from cyber threats. From the gridiron to high-security operations, Armilla is setting a new standard for communication in high-stakes environments.

About Armilla Tech

Armilla Tech develops advanced, secure communication solutions for high-stakes environments, including professional sports, law enforcement, and tactical operations. Its patented technology combines speed, clarity, and military-grade security to keep teams connected when it matters most.

Armilla Tech: Strong on the field. Unbreakable in the cloud. Ready for what’s next.

Media Contact
Company Name: Armilla Tech
Contact Person: Colleen Cole Velasquez
Email: Send Email
Phone: 310-739-8338
Country: United States
Website: www.armillatech.com

Goss Law Expands Legal Services in Sacramento with Unmatched Expertise and Dedication

Goss Law Expands Legal Services in Sacramento with Unmatched Expertise and Dedication
Goss Law is a premier Sacramento-based law firm specializing in criminal defense, domestic violence, and traffic law. Known for strategic advocacy and client-focused representation, the firm delivers strong legal support with professionalism and integrity. Goss Law is dedicated to protecting rights and achieving the best outcomes in complex legal matters.

Aug 19, 2025 – SACRAMENTO, CA – Known for professionalism, integrity, and results-driven advocacy, the firm provides essential legal services to individuals facing serious legal challenges throughout the Sacramento region.

Strengthening Criminal Defense Representation

Goss Law continues to build a reputation as a trusted Criminal Defense Attorney in Sacramento, delivering strategic legal defense for clients charged with misdemeanors and felonies. With a track record of successful outcomes, the firm focuses on safeguarding the rights and freedoms of individuals navigating complex criminal proceedings.

The firm’s legal team is highly experienced in a range of defense cases, including assault, DUI, drug offenses, theft, and more. Utilizing in-depth legal knowledge and a client-focused approach, Goss Law addresses each case with precision and care.

Expertise in Domestic Violence Defense

In cases involving accusations of abuse, Goss Law provides aggressive legal advocacy as a leading Domestic Violence Attorney in Sacramento. The firm prioritizes thorough investigations, strategic case development, and compelling defense strategies to protect the reputations and futures of those accused.

With a commitment to justice and fairness, Goss Law aims to ensure due process and defend against false or exaggerated claims in domestic violence matters.

Comprehensive Traffic Law Solutions

Traffic-related legal issues are also addressed efficiently and effectively by Goss Law’s team of skilled Traffic Lawyers Sacramento. From license suspensions to reckless driving charges, the firm delivers practical solutions and strong representation for individuals dealing with traffic citations and criminal driving allegations.

About Goss Law

Goss Law remains a vital resource for those in need of strong legal defense in Sacramento, demonstrating an unwavering commitment to excellence, results, and legal integrity. For more details, visit their website.

Media Contact
Company Name: Goss Law
Contact Person: Blair Goss
Email: Send Email
Phone: (916) 999-7689
Address:2000 L St #250
City: Sacramento
State: CA 95811
Country: United States
Website: https://www.goss.law/

Eurola Introduces Open Air Operable Louvre Retractable Pergola

Eurola Introduces Open Air Operable Louvre Retractable Pergola
Eurola unveils a sleek outdoor solution designed to shift with the day offering adaptable cover and style for both homes and commercial spaces.

Marrickville, NSW – August 18, 2025 – Eurola is now offering Open Air, a next-level operable louvre roof pergola with full retraction for clear sky moments and precise shade control. The system opens, tilts, and retracts into a compact stack for an outdoor area that adapts to sun, wind, and rain across homes and commercial spaces.

louvre-roof

Open Air louvered pergola arrives with single and double modules. A single module spans up to 4000 mm x 6000 mm, and a double module spans up to 8000 mm x 6000 mm. Standard colours include White (texture finish) and Anthracite, with custom powder coat options on request. Optional extras span LED strip lights, Somfy sun, wind, and rain sensors, motorised Solair sunscreens on selected sides, and multi-channel control upgrades.

“Customers ask for outdoor cover that moves at the pace of the day. Open Air gives that freedom. At lunch you can set full shade with a 150° louvre rotation, and at dusk you can clear the sky with full retraction. The cursive blade profile creates minimal stack, so the roof opens wide without bulky build-up in view. The result feels light, elegant, and easy to live with,” a spokesperson said.

Open Air louvered roof pergola fits as a free-standing feature or wall-mounted addition, with Somfy motor control by remote or wall switch. The aligned 210 mm blade closes flat for reliable rain cover, and the adjustable rotation manages light and airflow through the day. The design supports privacy and space partitioning through external sunscreens on one or more sides.

“Our engineering team focused on strength and longevity. Marine-grade alloys and 316 stainless components suit coastal installs, and the integrated guttering routes water away from living zones. Clients can add RGB lighting or white strip lighting for night use, plus Somfy motorisation for fingertip control,” the spokesperson explained.

Since its inception, Eurola focuses on louvred roof systems that perform, last, and look sharp. The team builds louvre and retractable solutions with precise control, reliable motorisation, and tidy water management for real-world use in Australian conditions. All their products are backed by strong warranties and responsive after-sales care, giving customers complete peace of mind.

For specifications and trade enquiries on louvre roof systems, customers shall consult with the team through the official website.

About Company:

Eurola is a family run manufacturing business offering a range of premium quality retractable roof systems designed to adapt with the Australasian climate. To know more, visit https://www.eurola.com.au/

Media Contact
Company Name: Eurola
Contact Person: Steve Nakousis
Email: Send Email
Phone: 02 9750 2211
Address:75-77 Railway Parade
City: Marrickville
State: NSW
Country: Australia
Website: https://www.eurola.com.au/

CYSM Shapers Explains What Makes Premium Shapewear With In-Depth Guide to Exclusive Technology Utilized in Their Products

CYSM Shapers is an American shapewear manufacturer with more than a million products sold during its 3+ decades in the industry.

CYSM Shapers has offered an in-depth showcase of some of the key innovation and technologies they have utilized in shapewear production in the past 30+ years of operation.

Initially launched with the goal of crafting shapewear to help post-operative recovery, CYSM has come a long way, incorporating technology that has helped transform body shapers from uncomfortable pieces of clothes worn only on special occasions to daily shapewear pieces with maximum comfort and even posture-related benefits.

Now, the team’s goal has become to allow every woman to feel beautiful, confident, and empowered.

“Our mission is to provide high-quality shapewear that enhances your natural curves while offering unmatched comfort and support. We’re passionate about helping you look and feel your best every day,” CYSM stated.

The company representative noted that to achieve their goal of daily shapewear, the team had to resort to using exclusive tech that no competitor used. One example of such features is the BIO Therapy Technology, exclusive to CYSM. It utilizes microcapsules embedded into the fabric to infuse marine algae straight onto the skin upon contact. That way, active ingredients help restore skin beauty, making it elastic and more youthful.

Furthermore, microcapsules help with antibacterial protection by battling bacteria and fungi, all to promote healthy skin and maintain a cool, fresh feeling for the wearer, with reduced moisture and lower temperatures.

The CYSM spokesperson added that utilizing multi-layered fabric was another key point of the production and development process through the years.

The premium CYSM fabric has multiple layers, starting with a high-compression layer at the top to help shape the user’s body, followed by a medium-compression inner layer to allow for greater freedom of movement, and then soft fabric close to the skin to keep the user comfortable and free of irritation.

“At CYSM Shapewear, we prioritize top-quality products made from the finest materials, ensuring comfort, durability, and performance through innovative design technologies,” the team stated. “Our fabric is soft, hypoallergenic, and prevents irritation, making it ideal for long-term wear. It promotes airflow and moisture control by creating a microclimate for all-day comfort and freshness.”

Inclusion is another key aspect of the CYSM approach, as the company became one of the industry trailblazers in promoting daily shapewear for plus-size women. Available sizes for all CYSM products start at S and go all the way up to 3XL. Shapers are equipped with adjustable straps for comfort, gradual abdominal compression, and hook closure for a perfect fit.

Every piece of CYSM shapewear in the Premium lineup is also certified under the OEKO-TEX Standard 100, which is a globally recognized testing and certification system for textiles. While the certification process is rigorous, it ensures that all shapewear that passes the test actually meets the highest standards for safety and quality.

“Our products undergo extensive testing for harmful substances, including Azo colorants, nickel, and other potentially harmful chemicals,” the team explained. “Certified as Class II, our shapewear is safe for prolonged skin contact and is suitable for post-surgery recovery.”

The spokesperson conculded by sharing a message, saying, “You should feel confident, not covered up. Stop hiding your body with oversized clothes. CYSM’s tummy control shapewear gently shapes with soft, high-quality fabrics and smart compression—so you can confidently show off your figure.”

Over the years, CYSM has crossed a major milestone of over one million products sold. A satisfied customer named Isabel wrote in her five-star review of one of the company’s Premium collection items: “I really enjoyed this product! It really shapes your figure and tightens without being uncomfortable. I can wear it underneath anything, and it doesn’t show! It’s the best, hands down!”

More information about CYSM Shapers, the company’s history, technology, and the full product lineup, can all be found on the official website.

Media Contact
Company Name: CYSM Shapers
Contact Person: CYSM Team
Email: Send Email
Phone: +13235861600
Address:5807 Pacific Blvd, Huntington Park, CA 90255
Country: United States
Website: https://cysm.com/

Encore, Encore… Broadway, TV Star Carole Demas Celebrating 85 Years of Life in a Special Encore Performance – Firefly

Saturday, Sept 6th, 7:00pm at 54 Below, Broadway’s Supper Club (www.54Below.org/CaroleDemas).

New York, NY, USA – August 18, 2025 – FIREFLY, features songs and memories from her storied career. With Special Guests, Paula Janis (TV’s Magic Garden) and Ilene Kristen (Broadway’s Grease).

ENCORE PERFORMANCE! 54 BELOW, Broadway’s Supper Club, presents the legendary Carole Demas, who holds the distinction of originating the roles of Sandy in Grease on Broadway, originating the title role of Stephen Schwartz’s The Baker’s Wife when it opened and numerous other roles on and off-Broadway in a SPECIAL ENCORE PERFORMANCE. She has performed on stage for more than six decades, including 2 years as Luisa in The Fantasticks at Sullivan Street Playhouse. Carole’s numerous television credits include The Magic Garden, PBS’ Showstoppers: Best of Broadway, and numerous guest starring roles on daytime and prime time programs. (www.54Below.org/CaroleDemas)

Joining Carole will be her MAGIC GARDEN Co-Star: Paula Janis, and original GREASE cast member: Ilene Kristen. She is accompanied by her longtime friend and exquisite Music Director, Ian Herman, plus Tom Hubbard on Bass and Dave Silliman on Drums.

FIREFLY:

“Unforgettable” – Broadway World (https://tinyurl.com/mv5jmz63)

“Magic on Steroids” – Nitelife Exchange. (https://tinyurl.com/2s4cdmn6)

“Her show, Firefly, was sheer perfection in performance and in the art of cabaret” – Marylin Lester

“Tonight at 54 Below, Carole Demas put on a breathtaking show…” – Michael Colby

Other Reviews of Carole…..

• “Superb, relevant and ageless entertainment” – Cabaret Scenes

• “Inspirational and absolutely stirring” – Marylin Lester

• “Wonderful, wonderful show” – Talkin’ Broadway

• “A joy throughout” – BistroAwards.com

• “Fills us with pleasure” – Theater Life

• “Carole Demas is a knockout in every possible way”. “Endearing and vocal best” – Nitelife Exchange

• “She was stunning. This show was stunning. Carole Demas is an inspiration” – Sue Matsuki

• “This mélange of life-affirming songs that glow in the talent and heartfelt performance … is like being refreshed and having faith renewed” – Rob Lester

Carole Demas

Carole Demas, Broadway and TV legend, Bistro Award Winner, stole the hearts of audiences and critics alike with her captivating and critically-acclaimed creation of Sandy in Broadway’s iconic, original GREASE. Her 65 year career has included thousands of leading role performances on and Off-Broadway and in regional theater. Carole originated the title role in the premiere production of Stephen Schwartz’s THE BAKER’S WIFE, in Los Angeles. Among her other roles: two years at New York’s Sullivan St. Playhouse as Luisa in THE FANTASTICKS and the creation of original ingénue leads in Fred Ebb’s MORNING SUN; RONDELAY (director Cyril Ritchard, choreographer Jacques d’Amboise); Oscar Brand’s HOW TO STEAL AN ELECTION (opposite Clifton Davis); Tom Jones & Harvey Schmidt’s PHILEMON and THE BONE ROOM among many others. In major regional theatres: Philia (A FUNNY THING HAPPENED ON THE WAY TO THE FORUM); Regina (ANOTHER PART OF THE FOREST); Angel (CELEBRATION); Wanda (ENTER LAUGHING); Corrie (BAREFOOT IN THE PARK, with Joan Bennett) and singing for the Champlain and NY Shakespeare Festivals for multiple seasons.

Carole played numerous guest star roles on classic prime time TV (including, KOJAK, MANNIX, ROUTE 66, BARNABY JONES, MAN FROM ATLANTIS, FANTASTIC JOURNEY (recently, BLUE BLOODS/CBS and ALLEGIANCE/NBC) and recurring roles on daytime dramas (EDGE OF NIGHT, ONE LIFE TO LIVE, AS THE WORLD TURNS). For the popular PBS Series GREAT PERFORMANCES, Carole joined other stars of the Great White Way for Lorimar’s SHOWSTOPPERS – THE BEST OF BROADWAY. On film, Carole starred in the 300 YEAR WEEKEND, with William Devane and THE SPACE WORKS for Trans-Lux Corp. Other films include appearances in: A LOVELY WAY TO DIE for Universal Films and THE DIS-APPOINTMENTS ROOM.

Her New York City concert and cabaret performances include: (BROADWAY ORIGINALS (Town Hall), OFF-BROADWAY CLOSE UP (Merkin Hall), 50th Anniversary celebrations for GREASE, WBAI Radio, Lincoln Center Library and The Fantasticks. She is seen in NYC’s favorite cabaret venues (Feinsteins/54 Below, Birdland, The Metropolitan Room, Laurie Beechman Theater, New World Stages annual gala, Le Poisson Rouge, The Iridium, The Triad-Stage 72, Signature Theatre, Urban Stages, Concerts For City Greens, etc.). She sang for BROADWAY TO BARBADOS for two seasons and recently headlined on Crystal Cruise, Film and Theatre Cruise to French Polynesia. She was a recurring favorite star in The Ziegfeld Society Productions. Her previous one-woman show in NYC and other locales (including The Caribbean Theatre, St. Croix) received rave reviews…”a powerhouse of musical theatre”, “a vocal champion”, “a consummate artist”, her voice has been described as “shimmering and thrilling with great warmth, sweetness and surprising power”. Her tribute to Jones and Schmidt THANK YOU FOR YOUR LOVE With Broadway’s Sarah Rice also garnered wonderful reviews. Her engaging, exciting cabaret and concert performances have brought funds and attention to many worthy causes, Most recently a sold out benefit concert in Rochester New York.

Carole starred (with lifelong friend Paula Janis) in TV’s most successful regional children’s series, THE MAGIC GARDEN (for over 12 years) leading to hundreds of live family concerts and recent viral posts on Facebook. Carole and Paula were inducted into the Long Island Music Hall of Fame. Carole’s versatility has been seen on camera in principal roles in over 200 commercials for television (everything from men’s cologne to peanut butter and often singing the jingles as well), among them Kodak, Promise Margarine, Lipton Tea, Puss ‘n Boots, Wonder Bread, M&M’s, Clairol, Timex, Lysol, AT&T, etc. more at www.caroledemas.com, www.caroleandpaula.com.

Musical Director: Ian Herman

Ian began his musical career studying classical piano. At the age of thirteen he was a guest soloist with the Pittsburgh Symphony Orchestra. After attending Manhattan School Of Music, Ian began working with performers including Jane Olivor, Donna McKechnie, Anita Morris, Judy Kaye, Liliane Montevecchi, Tom Andersen, Dawn Derow, Karen Mason, Sharon McNight, Carole J. Bufford, Marilyn Sokol, Angela LaGreca, Carole Demas, and Joy Behar in nightclubs in New York and around the country. In 1999 he received the Backstage Bistro Award for best Musical Director. He was a pianist and vocal coach at the Broadway revival of GREASE, working with guest stars such as Al Jarreau, Jon Secada, Sheena Easton, Chubby Checker, and Darlene Love. His other Broadway credits include JELLY’S LAST JAM, THE WHO’S TOMMY, SONG AND DANCE, and SWING, for which he wrote vocal and dance arrangements. and LAUGHING ROOM ONLY with Jackie Mason. He was also conductor for THE TOXIC AVENGER at New World Stages. Recently Ian released a new solo CD of all original pieces entitled Images.

MORE ABOUT 54 BELOW

54 Below, a recipient of the 2022 TONY AWARDS® Honor for Excellence in the Theatre, is a non-profit organization with a mission to preserve the music of Broadway and expand the art of the cabaret while growing opportunities for diverse communities of emerging and established artists and providing unparalleled audience experiences.

It was founded as a place for the Broadway community to celebrate Broadway performers, both established and new, who sing not only the music of Broadway and the Great American Songbook, but also new material intended for Broadway and off-Broadway stages. One of the most in demand venues in the city presenting over 700 shows per year, the club features fine dining and superb scenic, lighting, and sound designs entirely imagined by Broadway designers. For performers, writers, musicians, and more, 54 Below gives opportunities to advance their craft, expand their repertoires, and develop their voices in a way that is more personal, making them stronger as artists. It gives Broadway fans an opportunity to see their favorite artists in a different way, deepening their relationship and understanding of their talent.

54 Below celebrates Broadway musicals and writers of the past and present, promoting an ongoing engagement with their work. It is also a place for innovation in musical songwriting and performance. Collaborations born at 54 Below give rise to and help develop new theatrical projects and new musicals. In addition, its popular streaming video activities and audio recordings support these activities, helping to build a new Broadway audience worldwide, both in age and geography.

Located at 254 West 54th Street, the club presents live shows at 7pm and 9:30pm. Tickets and information at 54below.org.

Media Contact
Company Name: A.D.R. Studios, Inc.
Contact Person: Stuart Allyn
Email: Send Email
Phone: 914-591-5616
Country: United States
Website: http://www.adrinc.org

Footage Films Announces Limited Theatrical Release of Sci-Fi Thriller “RUN” on August 29, 2025

New film from director Chris Stokes combines alien invasion horror with survival thriller elements

LOS ANGELES, CA – August 18, 2025 – Footage Films has just announced the upcoming limited theatrical release of “RUN,” a sci-fi thriller that puts a deadly twist on the classic girls’ trip gone wrong. The film will hit select theaters nationwide on August 29, 2025.

Directed by Chris Stokes and co-written by Marques Houston, “RUN” stars Annie Ilonzeh, Marques Houston, Erica Mena, Erica Pinkett, and Drew Sidora in a heart-pounding story that begins as a simple getaway and transforms into a fight for survival.

The plot follows a group of friends whose weekend retreat takes a horrific turn when they discover a mutilated body in the woods. Their shock quickly turns to terror as breaking news reports reveal a full-scale alien attack spreading across the United States. Trapped between human and extraterrestrial threats, the group must use every resource at their disposal to stay alive.

“We wanted to create something that would keep audiences on the edge of their seats from start to finish,” said director Chris Stokes. “The film takes the familiar concept of friends in peril and adds layers that nobody will see coming. It’s about survival, trust, and the lengths people will go to protect each other when faced with the unthinkable.”

The ensemble cast brings together established television and film talent. Annie Ilonzeh, known for her roles in “Empire” and “All American,” leads the group alongside Marques Houston, who also served as co-writer. The cast is rounded out by Erica Mena (Love & Hip Hop), Erica Pinkett (Tales), and Drew Sidora (The Game).

Stokes, who previously directed films including “You Got Served” and “Somebody Help Me”, worked closely with Houston to craft a script that balances intimate character moments with high-stakes action sequences. The collaboration marks another creative partnership between the two, who have worked together on multiple projects over the years.

The film’s tagline, “IF YOU SEE THEM, RUN,” hints at the mysterious antagonists that drive the story’s central conflict. Without revealing too much, the filmmakers promise that audiences will face surprises that challenge their expectations about both the human and alien elements of the story.

“RUN” represents Footage Films’ continued commitment to producing genre entertainment that connects with audiences looking for original thrills. The company has built a reputation for creating films that combine strong performances with engaging storylines across multiple genres.

The limited theatrical release strategy allows the film to reach audiences in key markets while building word-of-mouth momentum. Footage Films plans to expand distribution based on initial audience response and critical reception.

Movie lovers can watch the official trailer and find additional information about cast, crew, and release locations at the film’s official website, https://runofficialmovie.com. The site also offers exclusive footage and updates on the release schedule.

Tickets for the August 29 release will be available through participating theater chains and online ticketing platforms. Additional release dates and locations will be announced as they become available.

About Footage Films

Footage Films is a United States-based production company focused on creating compelling entertainment across multiple genres. The company is committed to developing original stories that connect with diverse audiences.

Media Contact
Company Name: Footage Films
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://footage-films.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Footage Films Announces Limited Theatrical Release of Sci-Fi Thriller “RUN” on August 29, 2025